Workflow
Marti Technologies(MRT)
icon
Search documents
Marti Technologies(MRT) - 2024 Q4 - Annual Report
2025-04-29 21:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...
Marti Technologies(MRT) - 2024 H2 - Earnings Call Transcript
2025-04-29 17:50
Marti Technologies (MRT) H2 2024 Earnings Call April 29, 2025 01:50 PM ET Speaker0 and welcome to Marty Technologies Inc. Full Year twenty twenty four Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Cand Clyt Durgin, Founder and President. Thank you. Please go ahead. Speaker1 Thank you, Donna. Thank you, Donna. ...
Marti Technologies(MRT) - 2024 H2 - Earnings Call Presentation
2025-04-29 17:18
FY 2024 EARNINGS PRESENTATION NYSE American: MRT CAR-HAILING MOTORCYCLE-HAILING TAXI-HAILING E-BIKE E-MOPED E-SCOOTER Disclaimers Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be cove ...
Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN
Seeking Alpha· 2025-02-17 01:26
Monte Rosa Therapeutics (NASDAQ: GLUE ) is a biotechnology company working on oncology, autoimmune, and inflammatory diseases. But what makes GLUE special is that it uses its proprietary Quantitative and Engineered Elimination of Neosubstrates [QuEEN] platform to selectively produce molecular glue degraders. On top of that, this approachMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. deg ...
Marti Technologies: A Lofty But Realistic Guidance To Positive Free Cash Flow In 2025
Seeking Alpha· 2025-01-13 04:33
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in MRT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.This piece reflects my honest market outl ...
Unlocking Marti's $8 Billion Opportunity
Seeking Alpha· 2024-12-24 15:14
Marti Technologies, Inc. (NYSE: MRT ) is at an exciting inflection point, with the potential to lead the emerging ride-hailing market in Turkey. It has capitalized on its leading micromobility, including its ride-sharing position and a two-year investment to build a scaledYiannis Zourmpanos, founder of Yiazou IQ, an AI-driven stock research platform providing all-in-one stock reports. Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certif ...
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
GlobeNewswire News Room· 2024-12-05 12:00
Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients Recommended Phase 2 dose determined as 0.5 mg daily at a 21 days on, 7 days off drug dosing schedule Additional MRT-2359 Phase 1/2 study clinical results, including biomarker and activity data, anticipated in Q1 2025 BOSTON, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monte Rosa T ...
SIMPPLE LTD. Announces Sale and Deployment of 89 Autonomous Cleaning Robots Across Three Major MRT Lines in Singapore Operated By SMRT Trains
GlobeNewswire News Room· 2024-11-22 13:30
SINGAPORE, Nov. 22, 2024 (GLOBE NEWSWIRE) -- SIMPPLE Ltd. (NASDAQ: SPPL) (“SIMPPLE” or “the Company”), a leading technology provider and innovator in the facilities management sector, through its subsidiary, today announced that the Company had completed the sale and successful deployment of 89 autonomous cleaning robots across Singapore, marking the largest robotic fleet in the land transport sector with rail operator SMRT Trains. Aligned with the broader Singapore Government initiative to push towards gr ...
SIMPPLE Ltd. Announces Sale and Deployment of 89 Autonomous Cleaning Robots Across Three Major MRT Lines in Singapore Operated By SMRT Trains
GlobeNewswire News Room· 2024-11-22 13:30
Singapore, Nov. 22, 2024 (GLOBE NEWSWIRE) -- SIMPPLE Ltd. (NASDAQ: SPPL) (“SIMPPLE” or “the Company”), a leading technology provider and innovator in the facilities management sector, through its subsidiary, today announced that the Company had completed the sale and successful deployment of 89 autonomous cleaning robots across Singapore, marking the largest robotic fleet in the land transport sector with rail operator SMRT Trains. Aligned with the broader Singapore Government initiative to push towards gr ...
Marti Technologies(MRT) - 2024 Q2 - Earnings Call Transcript
2024-09-30 14:50
Marti Technologies, Inc. (NYSE:MRT) Q2 2024 Earnings Conference Call September 30, 2024 8:30 AM ET Company Participants Oguz Alper Oktem - Founder and Chief Executive Officer Cankut Durgun - Co-Founder and President Conference Call Participants Brett Knoblauch - Cantor Fitzgerald Poe Fratt from - Global Partners Operator Hello, everyone, and thank you for joining us for Marti's First Half 2024 Conference Call. Before we begin, I'd like to mention that today's presentation and earnings release are available ...